XASX
ACW
Market cap137mUSD
Oct 09, Last price
0.06AUD
1D
3.77%
1Q
25.00%
Jan 2017
-23.61%
IPO
-89.73%
Name
Actinogen Medical Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
17.89%
Rev. gr., 5y
9.32%
Revenues
0
-100.00%
Net income
-15m
L+4.40%
CFO
-18m
L+132.41%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11ß-HSD1 enzyme, is currently in Phase 2 clinical trials. This compound has demonstrated target engagement within the central nervous system and is being investigated for its potential in conditions such as Alzheimer's disease, depression with cognitive impairment, and the anxiety, sleep, and behavioral issues associated with fragile X syndrome. Founded in 1999, the company was formerly known as Actinogen Limited, adopting its current name in November 2015, and is headquartered in Sydney, Australia.
Key people
Chairman of the Board · since 2017
Jason Loveridge
Interim Non-Executive Chairman of the Board · since 2016
John William Ketelbey
Chief Executive Officer, Managing Director, Director · since 2014
Company Secretary · since 2013
Non-Executive Director · since 2019
George Morstyn
Non-Executive Director · since 2017
Anton Uvarov
Independent Non-Executive Director. · since 2013
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||